- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01614041
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder (TACGAD)
January 5, 2020 updated by: Sumitomo Pharma (Suzhou) Co., Ltd.
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial
The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
274
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China, 200065
- Shanghai Tongji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-65 years old
- Male or female
- Diagnosed with GAD according to DSM-IV
- HAMA score≥17
- Provide with written informed consent
- Agree to be washed-out for two weeks if receiving SSRI, SNRI or NASA.
Exclusion Criteria:
- Serious suicidal tendency
- The score of the sixth item of HAMA ≥3
- The score of HAMD ≥21
- Pregnant or lactating women
- History of allergic or hypersensitivity to tandospirone
- Serious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease
- Secondary anxiety disorders
- Drug or alcohol dependence within 1 year
- Patients currently taking benzodiazepine drugs
- Drivers and dangerous machine operators
- Participated in other clinical studies in the last 30 days
- Patients with clinically significant ECG or laboratory abnormalities
- Patients with a history of epilepsy
- Patients with abnormal TSH concentration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Group
Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
|
Usual dose treatment of Tandospirone, oral, 30 mg/day
|
Experimental: Study Group
Comparative high dose of tandospirone treatment, 60 mg/day
|
Comparative high dose of tandospirone treatment, oral, 60 mg/day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients whose Hamilton Anxiety Scale (HAMA) score change downwards ≥ 50% from baseline to 6 weeks treatment
Time Frame: 6 weeks
|
HAMA score changes downwards ≥ 50% indicate significant improvement; HAMA score changes downwards ≥ 75% indicate remission
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HAMA score changes from baseline to 6 weeks treatment
Time Frame: 6 weeks
|
Scores 14-21 indicate mild anxiety; scores 21-29 indicate moderate anxiety; scores over 29 indicate severe anxiety
|
6 weeks
|
Percentage of patients whose HAMA score ≤ 7 after 6 weeks treatment
Time Frame: 6 weeks
|
Scores ≤ 7 indicate non-anxious
|
6 weeks
|
HAMA factor score changes after treatment
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Wenyuan Wu, MD, Shanghai Tongji Hospital, Tongji University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 10, 2012
Primary Completion (Actual)
September 11, 2018
Study Completion (Actual)
July 1, 2019
Study Registration Dates
First Submitted
November 11, 2011
First Submitted That Met QC Criteria
June 6, 2012
First Posted (Estimate)
June 7, 2012
Study Record Updates
Last Update Posted (Actual)
January 7, 2020
Last Update Submitted That Met QC Criteria
January 5, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Disease
- Anxiety Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Tandospirone
Other Study ID Numbers
- DSPC-SED-1101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on Usual dose treatment of Tandospirone
-
Chongqing Medical UniversityUnknownComparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and AnxietyHypertension | AnxietyChina
-
University Hospital, MontpellierCompleted
-
Universitätsklinikum Hamburg-EppendorfCompletedPerioperative AnxietyGermany
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
Universitat Jaume IConsorcio Hospitalario Provincial de CastellónCompletedDepression | AnxietySpain
-
University Hospital, AkershusUniversity of OsloActive, not recruiting
-
Fu-Sheng WangUnknownHuman Immunodeficiency Virus | Disorder of Immune ReconstitutionChina
-
McMaster UniversityNot yet recruiting
-
Gaia AGRecruitingType 2 DiabetesGermany
-
Centre for Addiction and Mental HealthCompleted